Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2718 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2001  |  Volume : 12  |  Issue : 1  |  Page : 21-27
Comparison of Flow Panel Reactive Assay (PRA) TM Specific Test with Complement Dependent Cytotoxicity (CDC) to Define the HLA Antibodies Specificity: A Preliminary Study


Department of Pediatrics, King Hussein Medical Center, Amman, Jordan

Correspondence Address:
Adel Al-Wahadneh
Department of Pediatrics, King Hussein Medical Center, P.O. Box 540554, Amman
Jordan
Login to access the Email id


PMID: 18209356

Rights and Permissions

To determine the specificity of flow cytometry based assay for HLA antibody screening prior to transplantation, we evaluated 11 positive sera that were tested by both Flow Panel Reactive Assay (PRA) TM class I and class II specific beads after initial FlowPRA TM . HLA specificity was compared with previous data from the complement dependent cytotoxicity (CDC) testing of these samples. We found that five samples (22%) were more HLA class II specific (DR- or DQ-) by FlowPRA TM than CDC. One sample, negative by FlowPRA TM screening, was shown to be HLA class I and class II reactive by FlowPRA TM -specific test. Class I specificity was only defined by CDC in this sample. Two other samples, shown to be HLA class I and class II reactive by FlowPRA TM screening and FlowPRA TM -specific test, were found to be HLA class I reactive only in the first sample and HLA class II reactive only in the second sample by CDC. Our study suggests that FlowPRA TM -specific test has higher specificity and sensitivity than CDC in identification of HLA class II specificity than CDC. Nevertheless, FlowPRA TM -specific test failed to identify precisely the HLA specificity in samples with broad-spectrum specificity, such as those that have HLA specific antibodies directed against large number of shared epitopes. A software protocol for specificity analysis might help overcome this problem. Also, studies involving larger number of samples are required to validate our findings.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3853    
    Printed87    
    Emailed0    
    PDF Downloaded533    
    Comments [Add]    

Recommend this journal